Rudolph W, Dirschinger J, Reiniger G, Beyerle A, Hall D
Department of Cardiology, German Heart Center, Munich.
Eur Heart J. 1988 Jan;9 Suppl A:63-72. doi: 10.1093/eurheartj/9.suppl_a.63.
To address the issues of tolerance development and its circumvention during long-term treatment with nitrates, several controlled studies have been performed. In patients with coronary artery disease, during long-term treatment with isosorbide dinitrate (ISDN) in sustained-release form at dosages of 20 mg t.i.d., 40 mg t.i.d. and 60 mg t.i.d., both the rate of anginal attacks and the ischaemic reaction to exercise were unaffected. After a marked acute anti-ischaemic effect to 40 mg ISDN in nonsustained-release form, during chronic administration of the same dose four times daily, in association with continuously-high nitrate plasma concentrations, similarly, there were no significant effects. On use of nitroglycerin (NTG) transdermal patches delivering 10 mg, 15 mg and 30 mg per 24 hours, respectively, renewed patch application after 24 hours was not met with the same marked response observed after initial application. Clearly attenuated effects could be seen within 8 to 12 hours. These results show that tolerance development is incurred when the incrementation in plasma concentration after a repeated nitrate dose is of relatively limited magnitude with respect to baseline values. The observation of rapid reversibility of nitrate tolerance lead to the concept of interval treatment which on daily use incorporates a sufficiently long period without nitrate administration. On use of a nitrate-free treatment interval employing a regimen of 20 mg ISDN nonsustained-release form twice daily in the morning and at midday, 120 mg ISDN sustained-release form once daily or 50 or 100 mg isosorbide 5-mononitrate once daily, maintained effectiveness has been documented, as it has also been shown for treatment with NTG patches delivering 10 mg per 24 hours on incorporation of a 12-hour patch-free interval. The currently available patch system with discontinuous NTG delivery does not incur a complete loss of action but a considerable attenuation of its effects indicates the need for further refinements. Thus interval treatment guarantees maintenance of nitrate effects, albeit with the limitation that 24-hour therapeutic coverage is not enabled.
为解决硝酸盐长期治疗期间耐受性产生及其规避问题,已开展了多项对照研究。在冠心病患者中,使用缓释型二硝酸异山梨酯(ISDN)进行长期治疗,剂量分别为每日3次,每次20mg、40mg和60mg,心绞痛发作率和运动时的缺血反应均未受影响。在对非缓释型40mg ISDN产生显著急性抗缺血作用后,每日4次给予相同剂量进行长期给药,同时血浆硝酸盐浓度持续处于高水平,同样未产生显著影响。分别使用每24小时释放10mg、15mg和30mg硝酸甘油(NTG)的透皮贴剂,24小时后更换贴剂时,未出现初次使用时观察到的相同显著反应。在8至12小时内即可明显看出作用减弱。这些结果表明,当重复给予硝酸盐剂量后血浆浓度相对于基线值的增量幅度相对有限时,就会产生耐受性。硝酸盐耐受性快速可逆性的观察结果引出了间歇治疗的概念,即每日使用时包含一段足够长的无硝酸盐给药期。采用每日上午和中午各一次20mg非缓释型ISDN、每日一次120mg缓释型ISDN或每日一次50或100mg 5-单硝酸异山梨酯的无硝酸盐治疗间歇方案,已证明可维持疗效,同样,在每24小时释放10mg NTG的贴剂治疗中加入12小时的无贴剂间歇期也已证明有此效果。目前可用的具有间断释放NTG功能的贴剂系统不会导致作用完全丧失,但作用显著减弱表明需要进一步改进。因此,间歇治疗可保证硝酸盐作用的维持,尽管存在无法实现24小时治疗覆盖的局限性。